{"id":"cetuximab-injection","safety":{"commonSideEffects":[{"rate":"80–90","effect":"Acneiform rash"},{"rate":"25–30","effect":"Diarrhea"},{"rate":"20–25","effect":"Nausea"},{"rate":"15–20","effect":"Fatigue"},{"rate":"3–5","effect":"Infusion reactions"},{"rate":"13–17","effect":"Hypomagnesemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cetuximab binds to EGFR with high affinity, competitively inhibiting ligand binding and preventing receptor activation. This blocks downstream signaling pathways (MAPK and PI3K/AKT) that drive cell proliferation and survival. The antibody also recruits immune cells to mediate antibody-dependent cellular cytotoxicity (ADCC) against EGFR-expressing tumor cells.","oneSentence":"Cetuximab is a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) on cancer cells, preventing growth signals and inducing cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:05:25.088Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer (KRAS wild-type)"},{"name":"Head and neck squamous cell carcinoma"},{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT05355701","phase":"PHASE1","title":"A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-07-05","conditions":"Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer","enrollment":267},{"nctId":"NCT05063552","phase":"PHASE2, PHASE3","title":"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-13","conditions":"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma","enrollment":430},{"nctId":"NCT01810913","phase":"PHASE2, PHASE3","title":"Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-03-22","conditions":"Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7","enrollment":613},{"nctId":"NCT04892173","phase":"PHASE3","title":"JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC","status":"RECRUITING","sponsor":"Johnson & Johnson Enterprise Innovation Inc.","startDate":"2021-12-10","conditions":"Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged","enrollment":500},{"nctId":"NCT07463677","phase":"PHASE2","title":"Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-15","conditions":"Lung Cancer (NSCLC)","enrollment":55},{"nctId":"NCT07198841","phase":"PHASE2","title":"IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation","status":"RECRUITING","sponsor":"Guangdong Association of Clinical Trials","startDate":"2025-11-03","conditions":"Lung Cancer (Non-Small Cell)","enrollment":48},{"nctId":"NCT06984861","phase":"PHASE2","title":"A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-05-13","conditions":"Oropharyngeal Carcinoma","enrollment":74},{"nctId":"NCT05491512","phase":"PHASE2","title":"A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-08-04","conditions":"HPV, Throat Cancer, Oropharyngeal Carcinoma","enrollment":121},{"nctId":"NCT06835569","phase":"PHASE1","title":"A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations","status":"RECRUITING","sponsor":"Alterome Therapeutics, Inc.","startDate":"2025-03-05","conditions":"Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer)","enrollment":188},{"nctId":"NCT06239220","phase":"PHASE2","title":"PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC","status":"RECRUITING","sponsor":"Glenn J. Hanna","startDate":"2024-02-16","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer","enrollment":25},{"nctId":"NCT07435311","phase":"PHASE1","title":"A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2020-06-15","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":118},{"nctId":"NCT07435324","phase":"PHASE3","title":"A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"R-Pharm","startDate":"2024-08-08","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":161},{"nctId":"NCT07217028","phase":"PHASE1","title":"Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2026-04","conditions":"SCC - Squamous Cell Carcinoma, Radiotracer, Head and Neck Squamous Cell Carcinoma","enrollment":60},{"nctId":"NCT07391618","phase":"PHASE2","title":"Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-05-15","conditions":"Advanced Colorectal Cancer","enrollment":583},{"nctId":"NCT06194656","phase":"PHASE2","title":"Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Shanghai Institute Of Biological Products","startDate":"2024-09-27","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":81},{"nctId":"NCT07327411","phase":"PHASE2","title":"Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2025-12-27","conditions":"Advanced Refractory Solid Tumors","enrollment":40},{"nctId":"NCT07309289","phase":"PHASE3","title":"NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-07-01","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":144},{"nctId":"NCT07302841","phase":"PHASE4","title":"Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-01-20","conditions":"Pancreatic Cancer Non-resectable","enrollment":28},{"nctId":"NCT06725368","phase":"PHASE2","title":"Carboplatin + Paclitaxel + Cetuximab (PCC) After Failure of Pembrolizumab +/- First-line Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"RECRUITING","sponsor":"Centre Paul Strauss","startDate":"2025-01-24","conditions":"Head and Neck Cancer","enrollment":46},{"nctId":"NCT06540326","phase":"PHASE2","title":"Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-11-12","conditions":"Colorectal Cancer Metastatic","enrollment":100},{"nctId":"NCT07294261","phase":"PHASE2","title":"Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-12-23","conditions":"Local Advanced or Metastatic NSCLC","enrollment":69},{"nctId":"NCT06385925","phase":"PHASE1, PHASE2","title":"A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","status":"RECRUITING","sponsor":"Tyligand Pharmaceuticals (Suzhou) Limited","startDate":"2024-04-29","conditions":"Malignant Neoplasm","enrollment":440},{"nctId":"NCT06385678","phase":"PHASE1, PHASE2","title":"A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-07-05","conditions":"Advanced KRAS G12D Mutant Solid Tumors","enrollment":47},{"nctId":"NCT04607421","phase":"PHASE3","title":"A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-12-21","conditions":"Neoplasms","enrollment":831},{"nctId":"NCT05619172","phase":"PHASE2","title":"A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer","status":"TERMINATED","sponsor":"SOTIO Biotech AG","startDate":"2022-12-22","conditions":"Colorectal Cancer","enrollment":16},{"nctId":"NCT07059221","phase":"PHASE1, PHASE2","title":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-07-11","conditions":"Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","enrollment":96},{"nctId":"NCT07070713","phase":"PHASE2","title":"Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-07-30","conditions":"Metastatic Colorectal Cancer With Left-sided Primary Tumor, Immunotherapy","enrollment":44},{"nctId":"NCT06980454","phase":"PHASE1","title":"Phase I PK Comparison of HLX05 vs. Erbitux® in Healthy Chinese Males: Safety, Immunogenicity, and Pharmacokinetics","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2025-06-04","conditions":"Cancer, mCRC","enrollment":322},{"nctId":"NCT07044921","phase":"PHASE2","title":"Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2024-09-01","conditions":"Colorectal Cancer Metastatic","enrollment":30},{"nctId":"NCT06959589","phase":"PHASE2","title":"The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-06-01","conditions":"Colorectal Cancer Metastatic, KRAS G12C Mutation","enrollment":50},{"nctId":"NCT06959693","phase":"PHASE2, PHASE3","title":"A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-06-01","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":590},{"nctId":"NCT03647423","phase":"PHASE1, PHASE2","title":"QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-08-31","conditions":"Chordoma, Unresectable Malignant Neoplasm","enrollment":""},{"nctId":"NCT05894694","phase":"PHASE4","title":"Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","startDate":"2023-09-27","conditions":"Advanced Colorectal Carcinoma","enrollment":320},{"nctId":"NCT03563157","phase":"PHASE1, PHASE2","title":"QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2018-09-28","conditions":"Colorectal Cancer Metastatic, mCRC","enrollment":2},{"nctId":"NCT04474470","phase":"PHASE1, PHASE2","title":"A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer","status":"COMPLETED","sponsor":"TyrNovo Ltd.","startDate":"2020-09-03","conditions":"Solid Tumor, Adult, Squamous Cell Carcinoma of Head and Neck, Colorectal Adenocarcinoma","enrollment":52},{"nctId":"NCT06603376","phase":"PHASE2","title":"Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2024-09-01","conditions":"Colorectal Carcinoma","enrollment":75},{"nctId":"NCT06309043","phase":"PHASE1","title":"A Randomized, Single Intravenous Dose, Parallel Phase I Clinical Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX05 Vs. Erbitux® (Cetuximab) in Healthy Adult Male Chinese Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2024-04-22","conditions":"EGFR Overexpression","enrollment":268},{"nctId":"NCT06225622","phase":"PHASE1","title":"Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-03-11","conditions":"Metastatic Colorectal Cancer","enrollment":78},{"nctId":"NCT05203601","phase":"PHASE1","title":"A Phase Ⅰa Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors.","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2020-11-26","conditions":"Tumor","enrollment":36},{"nctId":"NCT05260671","phase":"PHASE2","title":"Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2022-01-25","conditions":"Head and Neck Neoplasms, Recurrent Disease, Metastatic Cancer","enrollment":48},{"nctId":"NCT03727724","phase":"PHASE2","title":"Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2018-12-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":37},{"nctId":"NCT06035133","phase":"NA","title":"Treatment of Low Locally Advanced Rectal Cancer With Radiotherapy Removal TNT Plus Neoadjuvant Therapy","status":"NOT_YET_RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2023-11-10","conditions":"Rectal Cancer","enrollment":213},{"nctId":"NCT02499120","phase":"PHASE2","title":"Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-09-10","conditions":"Squamous Cell Carcinoma of the Head and Neck (SCCHN)","enrollment":125},{"nctId":"NCT04984369","phase":"PHASE2","title":"The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2021-08-11","conditions":"CRC","enrollment":50},{"nctId":"NCT05929456","phase":"PHASE1","title":"Multispectral Bimodal Fluorescence Guided Surgery of High-grade Glioma With Cetuximab-800CW and 5-ALA (5-aminolevulinic Acid)","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2023-05-05","conditions":"Glioblastoma, High-grade Glioma","enrollment":21},{"nctId":"NCT05751512","phase":"PHASE3","title":"A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN","status":"UNKNOWN","sponsor":"Shanghai Miracogen Inc.","startDate":"2023-03","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":180},{"nctId":"NCT04856631","phase":"PHASE1, PHASE2","title":"A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer","status":"UNKNOWN","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2021-04-06","conditions":"Head and Neck Squamous Cell Cancer","enrollment":88},{"nctId":"NCT00115700","phase":"PHASE3","title":"Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma","status":"COMPLETED","sponsor":"Trans Tasman Radiation Oncology Group","startDate":"2000-02","conditions":"Follicular Lymphoma","enrollment":150},{"nctId":"NCT02105636","phase":"PHASE3","title":"Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-05-29","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":361},{"nctId":"NCT01592721","phase":"PHASE1, PHASE2","title":"Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2013-04","conditions":"Squamous Cell Carcinoma, Head and Neck Cancer","enrollment":6},{"nctId":"NCT05544812","phase":"","title":"A Small-sample, Real-world Study of Sintilimab Plus Bevacizumab/Cetuximab Plus XELOX Regimen for Conversion Therapy in Patients With Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2022-05-01","conditions":"Colorectal Cancer","enrollment":10},{"nctId":"NCT04065555","phase":"EARLY_PHASE1","title":"Intratumoral Microdosing of TAK-981 in Head and Neck Cancer","status":"COMPLETED","sponsor":"Presage Biosciences","startDate":"2020-10-07","conditions":"Head and Neck Cancer","enrollment":12},{"nctId":"NCT05468177","phase":"PHASE2","title":"Cetuximab in Combination With Anti-PD-1 and mFOLFOX Treat For RAS/BRAF wt Right-Sided Colon Cancer","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2022-08-01","conditions":"Colonic Neoplasms","enrollment":66},{"nctId":"NCT05019534","phase":"PHASE1","title":"Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2021-08-15","conditions":"BRAF V600E-mutated /MSS Metastatic Colorectal Cancer, Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody","enrollment":12},{"nctId":"NCT00381706","phase":"PHASE2","title":"Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2006-09-15","conditions":"Esophageal Cancer","enrollment":245},{"nctId":"NCT03286738","phase":"","title":"Pattern of Use of Bevacizumab or Cetuximab + FOLFIRI Regimen as First-line Treatment in Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Joong Bae Ahn","startDate":"2015-11","conditions":"Metastatic Colorectal Cancer","enrollment":1800},{"nctId":"NCT03563170","phase":"PHASE1, PHASE2","title":"QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-25","conditions":"Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent","enrollment":""},{"nctId":"NCT03608046","phase":"PHASE2","title":"Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer","status":"UNKNOWN","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2018-10-03","conditions":"Colorectal Neoplasms, Malignant","enrollment":59},{"nctId":"NCT01741038","phase":"PHASE2, PHASE3","title":"AlloStim® In-Situ Vaccine in Pre-Treated Metastatic Colorectal Cancer","status":"WITHDRAWN","sponsor":"Mirror Biologics, Inc.","startDate":"2017-12","conditions":"Metastatic Colorectal Cancer","enrollment":""},{"nctId":"NCT03491709","phase":"PHASE1","title":"A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCC","status":"UNKNOWN","sponsor":"Dragonboat Biopharmaceutical Company Limited","startDate":"2018-07-01","conditions":"Colorectal Cancer","enrollment":18},{"nctId":"NCT02277197","phase":"PHASE1","title":"Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)","status":"COMPLETED","sponsor":"James J Lee","startDate":"2015-08","conditions":"Carcinoma, Squamous Cell of Head and Neck, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head And Neck","enrollment":14},{"nctId":"NCT00403052","phase":"PHASE1","title":"A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Dynavax Technologies Corporation","startDate":"2006-11","conditions":"Colorectal Neoplasms","enrollment":14},{"nctId":"NCT03881787","phase":"PHASE1","title":"Clinical Trial to Evaluate Pharmacokinetics,Safety and Immunogenicity of Single Injection of CDP1 to Healthy Volunteers Compared to Erbitux","status":"UNKNOWN","sponsor":"Dragonboat Biopharmaceutical Company Limited","startDate":"2019-02-27","conditions":"Healthy Volunteers","enrollment":84},{"nctId":"NCT03356158","phase":"PHASE1","title":"A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2017-11-15","conditions":"Metastatic Colorectal Cancer","enrollment":21},{"nctId":"NCT00077233","phase":"PHASE3","title":"FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2003-12","conditions":"Colorectal Cancer","enrollment":238},{"nctId":"NCT00540943","phase":"PHASE1","title":"Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-13","conditions":"Neoplasms, Colorectal","enrollment":25},{"nctId":"NCT01895257","phase":"PHASE3","title":"Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal Cancer","status":"UNKNOWN","sponsor":"Universiteit Antwerpen","startDate":"2013-08","conditions":"Colorectal Cancer","enrollment":162},{"nctId":"NCT01467115","phase":"PHASE2","title":"Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer","status":"COMPLETED","sponsor":"Drexel University College of Medicine","startDate":"2010-03","conditions":"Head and Neck Cancer","enrollment":1},{"nctId":"NCT00903461","phase":"PHASE1","title":"Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"University of Pittsburgh","startDate":"2012-04","conditions":"Carcinoma, Squamous Cell of Head and Neck, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head And Neck","enrollment":7},{"nctId":"NCT01040832","phase":"PHASE2","title":"EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2009-12","conditions":"Squamous Cell Carcinoma of the Head and Neck Cancer","enrollment":107},{"nctId":"NCT00874848","phase":"PHASE2","title":"Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"HiberCell, Inc.","startDate":"2009-08","conditions":"NSCLC","enrollment":90},{"nctId":"NCT02845999","phase":"PHASE1","title":"Allogenic Immunotherapy Based on Natural Killer (NK) Cell Adoptive Transfer in Metastatic Gastrointestinal Carcinoma Treated With Cetuximab","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2009-11","conditions":"Gastrointestinal Metastatic Cancer","enrollment":9},{"nctId":"NCT00514943","phase":"PHASE2","title":"BIBW 2992 (Afatinib) in Head & Neck Cancer","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-08","conditions":"Head and Neck Neoplasms, Carcinoma, Squamous Cell","enrollment":124},{"nctId":"NCT00633464","phase":"PHASE2","title":"Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2008-06","conditions":"Triple Negative Locally Advanced Non-resectable Breast Cancer, Metastatic Breast Cancer","enrollment":79},{"nctId":"NCT01030042","phase":"PHASE3","title":"Trial Comparing Two Two Sequences of Therapy in Colorectal Metastatic Patients","status":"COMPLETED","sponsor":"Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente","startDate":"2009-09","conditions":"Metastatic Colorectal Cancer","enrollment":110},{"nctId":"NCT00691548","phase":"PHASE1","title":"Non-invasive Imaging of Cetuximab-Zr. 89 Uptake Wit PET: a Phase I Trial in Stage IV Cancer Patients","status":"COMPLETED","sponsor":"Maastricht Radiation Oncology","startDate":"2009-06","conditions":"Stage IV Cancer","enrollment":9},{"nctId":"NCT01360827","phase":"PHASE1","title":"EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2010-08","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":13},{"nctId":"NCT01068132","phase":"PHASE2","title":"Prognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab.","status":"COMPLETED","sponsor":"Regione Lombardia","startDate":"2009-04","conditions":"Colorectal Cancer","enrollment":54},{"nctId":"NCT00719199","phase":"PHASE1","title":"Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer","status":"TERMINATED","sponsor":"EMD Serono","startDate":"2009-01","conditions":"Colorectal Cancer","enrollment":21},{"nctId":"NCT01057589","phase":"PHASE2","title":"A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-02","conditions":"Head and Neck Neoplasms","enrollment":66},{"nctId":"NCT00496236","phase":"PHASE1, PHASE2","title":"Radiotherapy, Cetuximab, and Injections of TNFerade™ Biologic for Elderly or Frail Patients With Head and Neck Cancer","status":"COMPLETED","sponsor":"GenVec","startDate":"","conditions":"Head and Neck Cancer, Head and Neck Neoplasms","enrollment":""},{"nctId":"NCT00912327","phase":"","title":"Efficacy and Safety Study of Imprime PGG With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer","status":"COMPLETED","sponsor":"HiberCell, Inc.","startDate":"2009-06","conditions":"Colorectal Cancer","enrollment":18},{"nctId":"NCT00502567","phase":"PHASE1","title":"A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-01","conditions":"Advanced Solid Tumor","enrollment":104},{"nctId":"NCT00518193","phase":"PHASE2","title":"Phase II Study , Association of Cisplatine Topotecan and Cetuximab in Patients Whith Late or in Progress Epithelial Cancer of the Cervix","status":"TERMINATED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2007-04","conditions":"Cervix Cancer","enrollment":44},{"nctId":"NCT00815308","phase":"PHASE2","title":"Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2009-01","conditions":"Esophageal Cancer","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":188,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Erbitux"],"phase":"phase_3","status":"active","brandName":"Cetuximab injection","genericName":"Cetuximab injection","companyName":"Shanghai Miracogen Inc.","companyId":"shanghai-miracogen-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cetuximab is a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) on cancer cells, preventing growth signals and inducing cell death. Used for Metastatic colorectal cancer (KRAS wild-type), Head and neck squamous cell carcinoma, Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":2,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2004-02-12T00:00:00.000Z","mah":"IMCLONE","brand_name_local":"ERBITUX","application_number":"BLA125084"}],"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}